Ovarian cancer has always been a perplexing problem to the clinicians. Most cases are detected at an advanced stage with poor and unpredictable response to therapy. Screening of ovarian cancer in general population has not proved to the useful due to low sensitivities of the available tests. There is need for newer tests which can overcome these problems clinicians are facing. Remarkable advances in the field of genetics and molecular techniques have given clinicians a hope for not only early diagnosis but also to monitor response to therapy and detect early recurrences and resistance to drugs. Circulating cell free DNA and circulating tumour cells have given a new hope, though it still hasprove its effectiveness in routine clinical use. This article throws light on these newer developments in ovarian cancer.

Keywords: Circulating Tumour Cells; Circulating Cell Free Tumour DNA; Ovarian Cancer.